Extracorporeal photopheresis improves nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: Three case reports and review of literature

Journal of Clinical Apheresis

Volumn 23, Issue 4, 2008, Pages 144-150

  Mathur, Kiran ^a   Morris, Scott ^b   Deighan, Chris ^b   Green, Rachel ^c   Douglas, Kenneth William ^a  

^a BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^b GLASGOW ROYAL INFIRMARY   (United Kingdom)

^c SCOTTISH NATIONAL BLOOD TRANSFUSION SERVICE   (United Kingdom)

Author keywords

Extracorporeal photopheresis; Gadolinium; Nephrogenic fibrosing dermopathy; Nephrogenic systemic fibrosis; Therakos UVAR XTS

Indexed keywords

GADODIAMIDE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANAMNESIS; ARTICLE; CASE REPORT; CELLULITIS; CLINICAL PROTOCOL; DAILY LIFE ACTIVITY; DEVICE; DISEASE DURATION; EXTRACORPOREAL PHOTOPHERESIS; FEMALE; FLEXION CONTRACTURE; HEMODIALYSIS; HUMAN; HUMAN TISSUE; HYPOTENSION; KIDNEY FAILURE; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; NEPHRECTOMY; NEPHROGENIC FIBROSING DERMOPATHY; NEPHROLITHIASIS; PUVA; RANGE OF MOTION; RENAL REPLACEMENT THERAPY; SKIN BIOPSY; SYMPTOM;

AGED; FEMALE; FIBROSIS; HUMANS; JOINT DISEASES; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PHOTOPHERESIS; SKIN DISEASES; TIME FACTORS;

EID: 51749116890     PISSN: 07332459     EISSN: 10981101     Source Type: Journal    
DOI: 10.1002/jca.20170     Document Type: Article

References (20)

1. Cowper SE, Su LD, Bhawan J, Robin HS, LeBoit PE. Nephrogenic fibrosing dermopathy. Am J Dermatopathol 2001;23:383-393.
2. Cassis TB, Jackson JM, Sonnier GB, Callen JP. Nephrogenic fibrosing dermopathy in a patient with acute renal failure never requiring dialysis. Int J Dermatol 2006;45:56-59.
3. Gillet M, Cozzio A, Burg G, Nestle FO. Successful treatment of nephrogenic fibrosing dermopathy with extracorporeal photopheresis. Br J Dermatol 2005;152:531-536.
4. Quan TE, Cowper SE, Wu SP, Bockenstedt LK, Bucala R. Circulating fibrocytes: collagen secreting cells of the peripheral blood. Int J Biochem Cell Biol 2004;36:598-606.
5. Jimenez SA, Artlett CM, Sandorfi N, Derk C, Latinis K, Sawaya H, Haddad R, Shanahan JC. Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor beta1 expression in affected skin. Arthr Rheum 2004;50:2660-2666.
6. Centre for Drug Evaluation and Research. US Food and Drug Administration Web site. Public health advisory: update on magnetic resonance imaging contrast agents containing gadolinium and nephrogenic fibrosing dermopathy. Available at: http//www.fda.gov/cder/drug/advisory/ gadolinium_agents.htm (Dec. 22, 2006).
7. Peak AS, Sheller A. Risk factors for developing gadolinium-induced nephrogenic systemic fibrosis. Ann Pharmacother 2007;41: 1481-1485.
8. Swaminathan S, Ahmed I, McCarthy JT, Albright RC, Pittelkow MR, Caplice NM, Griffin MD, Leung N. Nephrogenic fibrosing dermopathy and high-dose erythropoietin therapy. Ann Int Med 2006;145:234-235.
9. CowperShawn E. Nephrogenic fibrosing dermopathy: the first 6 years. Curr Opin Rheumatol 2003;15:785-790.
10. Cowper SE. The International Centre for Nephrogenic Fibrosing Dermopathy Research (ICNFDR). Available at www.icnfdr.org (updated Feb. 7, 2007).
11. Rook AH, Freundlich B, Jegasothy BV, Perez MI, Barr WG, Jimenez SA, Rietschel RL, Wintroub B, Kahaleh MB, Varga J. Treatment of systemic sclerosis with extracorporeal photochemotherapy. Results of a multicentre trial. Arch Dermatol 1992;128:337-346.
12. Pesek G, Tyler J, Theus J, Nakagawa M, Pellowski D, Cortex-Fox M. Extracorporeal photopheresis, a promising treatment for nephrogenic fibrosing dermopathy. Presented at the 27th Annual Meeting of American Society for Apheresis, May 24-26, 2006.
13. McKenna KE, Whittaker S, Rhodes LE, Taylor P, Lloyd J, Ibbotson S, Russell-Jones R (British Photodermatology Group and UK Skin Lymphoma Group). Evidence-based practice of photopheresis 1987-2001: a report of a workshop of the British Photodermatology Group and the U.K. Skin Lymphoma Group. Br J Dermatol 2006;154:7-20.
14. Couriel DR, Hosing C, Saliba R, Shpall EJ, Anderlini P, Rhodes B, Smith V, Khouri I, Giralt S, De Lima M, Hsu Y, Ghosh S, Neumann J, Andersson B, Qazilbash M, Hymes S, Kim S, Champlin R, Donato M. Extracorporeal photochemotherapy for the treatment of steroid resistant chronic GvHD. Blood 2006;107: 3074-3080.
15. Dupont A, Majithia V, Ahmad S, McMurray R. Nephrogenic systemic fibrosis, a new mimicker of systemic fibrosis. Am J Med Sci 2005;330:192-194.
16. Mendoza FA, Artlett CM, Sandorfi N, Latinis K, Piera-Velazquez S, Jimenez SA. Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. Semin Arthr Rheumat 2006;35:238-249.
17. Boyd AS, Zic JA, Abraham JL. Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 2007;56: 27-30.
18. Grobner T. Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006;21:1104-1108.
19. Daram SR, Cortese MC, Basanti B. Nephrogenic fibrosing dermopathy/ nephrogenic systemic fibrosis: report of a new case with literature review. Am J Kid Dis 2005;46:754-759.
20. Nephrogenic systemic fibrosis. Healthcare professional communication. Available at www.mhra.gov.uk (Feb. 7, 2007).